Considerable variability in platelet activity among patients with coronary artery disease in response to an increased maintenance dose of clopidogrel

Julie H. Oestreich, John Holt, Steven P. Dunn, Susan S. Smyth, Charles Campbell, Richard Charnigo, Wendell S. Akers, Steven R. Steinhubl

Research output: Contribution to journalReview article

13 Citations (Scopus)

Abstract

BACKGROUND: Variable platelet response to clopidogrel has been widely observed. Studies have shown that the mean aggregation response to clopidogrel can be changed by a higher maintenance dose. However, these studies have not focused on individual changes. OBJECTIVES: This study examined the platelet function effects of increasing the maintenance clopidogrel dose from 75 to 150 mg/day with a focus on inter-individual response. PATIENTS/METHODS: Twenty patients with known coronary artery disease receiving 75 mg/day clopidogrel were recruited and given 150 mg/day clopidogrel for 30 days, then returned to 75 mg/day for an additional 30 days. Platelet function was assessed through light-transmittance aggregometry (LTA) and the VerifyNow P2Y12 assay at baseline, 30 days, and 60 days. RESULTS: Mean platelet inhibition was significantly improved with the increased maintenance dose when measured by the VerifyNow P2Y12 assay (P2Y12 reaction units: 191±15 vs. 158±17, P=0.013), but not when measured by LTA (LTA-adenosine diphosphate 5: 40±3 vs. 36±3, P = 0.11; LTA-adenosine diphosphate 20: 50±3 vs. 47±3, P = 0.23). However, only 50% of individual patients experienced improved platelet inhibition, as measured by the VerifyNow P2Y12 assay, when treated with the increased maintenance dose. Furthermore, poor baseline platelet response did not predict improved responsiveness at the increased dose. CONCLUSION: Despite changing the population's mean antiplatelet response, an increased maintenance dose of clopidogrel did not improve antiplatelet response in a substantial number of patients; nor did baseline platelet function predict response to a higher maintenance dose.

Original languageEnglish (US)
Pages (from-to)207-213
Number of pages7
JournalCoronary Artery Disease
Volume20
Issue number3
DOIs
StatePublished - May 1 2009

Fingerprint

clopidogrel
Coronary Artery Disease
Blood Platelets
Light
Adenosine Diphosphate

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

Considerable variability in platelet activity among patients with coronary artery disease in response to an increased maintenance dose of clopidogrel. / Oestreich, Julie H.; Holt, John; Dunn, Steven P.; Smyth, Susan S.; Campbell, Charles; Charnigo, Richard; Akers, Wendell S.; Steinhubl, Steven R.

In: Coronary Artery Disease, Vol. 20, No. 3, 01.05.2009, p. 207-213.

Research output: Contribution to journalReview article

Oestreich, Julie H. ; Holt, John ; Dunn, Steven P. ; Smyth, Susan S. ; Campbell, Charles ; Charnigo, Richard ; Akers, Wendell S. ; Steinhubl, Steven R. / Considerable variability in platelet activity among patients with coronary artery disease in response to an increased maintenance dose of clopidogrel. In: Coronary Artery Disease. 2009 ; Vol. 20, No. 3. pp. 207-213.
@article{6d8a805e419b49708aa1f60515f323c3,
title = "Considerable variability in platelet activity among patients with coronary artery disease in response to an increased maintenance dose of clopidogrel",
abstract = "BACKGROUND: Variable platelet response to clopidogrel has been widely observed. Studies have shown that the mean aggregation response to clopidogrel can be changed by a higher maintenance dose. However, these studies have not focused on individual changes. OBJECTIVES: This study examined the platelet function effects of increasing the maintenance clopidogrel dose from 75 to 150 mg/day with a focus on inter-individual response. PATIENTS/METHODS: Twenty patients with known coronary artery disease receiving 75 mg/day clopidogrel were recruited and given 150 mg/day clopidogrel for 30 days, then returned to 75 mg/day for an additional 30 days. Platelet function was assessed through light-transmittance aggregometry (LTA) and the VerifyNow P2Y12 assay at baseline, 30 days, and 60 days. RESULTS: Mean platelet inhibition was significantly improved with the increased maintenance dose when measured by the VerifyNow P2Y12 assay (P2Y12 reaction units: 191±15 vs. 158±17, P=0.013), but not when measured by LTA (LTA-adenosine diphosphate 5: 40±3 vs. 36±3, P = 0.11; LTA-adenosine diphosphate 20: 50±3 vs. 47±3, P = 0.23). However, only 50{\%} of individual patients experienced improved platelet inhibition, as measured by the VerifyNow P2Y12 assay, when treated with the increased maintenance dose. Furthermore, poor baseline platelet response did not predict improved responsiveness at the increased dose. CONCLUSION: Despite changing the population's mean antiplatelet response, an increased maintenance dose of clopidogrel did not improve antiplatelet response in a substantial number of patients; nor did baseline platelet function predict response to a higher maintenance dose.",
author = "Oestreich, {Julie H.} and John Holt and Dunn, {Steven P.} and Smyth, {Susan S.} and Charles Campbell and Richard Charnigo and Akers, {Wendell S.} and Steinhubl, {Steven R.}",
year = "2009",
month = "5",
day = "1",
doi = "10.1097/MCA.0b013e328329924b",
language = "English (US)",
volume = "20",
pages = "207--213",
journal = "Coronary Artery Disease",
issn = "0954-6928",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Considerable variability in platelet activity among patients with coronary artery disease in response to an increased maintenance dose of clopidogrel

AU - Oestreich, Julie H.

AU - Holt, John

AU - Dunn, Steven P.

AU - Smyth, Susan S.

AU - Campbell, Charles

AU - Charnigo, Richard

AU - Akers, Wendell S.

AU - Steinhubl, Steven R.

PY - 2009/5/1

Y1 - 2009/5/1

N2 - BACKGROUND: Variable platelet response to clopidogrel has been widely observed. Studies have shown that the mean aggregation response to clopidogrel can be changed by a higher maintenance dose. However, these studies have not focused on individual changes. OBJECTIVES: This study examined the platelet function effects of increasing the maintenance clopidogrel dose from 75 to 150 mg/day with a focus on inter-individual response. PATIENTS/METHODS: Twenty patients with known coronary artery disease receiving 75 mg/day clopidogrel were recruited and given 150 mg/day clopidogrel for 30 days, then returned to 75 mg/day for an additional 30 days. Platelet function was assessed through light-transmittance aggregometry (LTA) and the VerifyNow P2Y12 assay at baseline, 30 days, and 60 days. RESULTS: Mean platelet inhibition was significantly improved with the increased maintenance dose when measured by the VerifyNow P2Y12 assay (P2Y12 reaction units: 191±15 vs. 158±17, P=0.013), but not when measured by LTA (LTA-adenosine diphosphate 5: 40±3 vs. 36±3, P = 0.11; LTA-adenosine diphosphate 20: 50±3 vs. 47±3, P = 0.23). However, only 50% of individual patients experienced improved platelet inhibition, as measured by the VerifyNow P2Y12 assay, when treated with the increased maintenance dose. Furthermore, poor baseline platelet response did not predict improved responsiveness at the increased dose. CONCLUSION: Despite changing the population's mean antiplatelet response, an increased maintenance dose of clopidogrel did not improve antiplatelet response in a substantial number of patients; nor did baseline platelet function predict response to a higher maintenance dose.

AB - BACKGROUND: Variable platelet response to clopidogrel has been widely observed. Studies have shown that the mean aggregation response to clopidogrel can be changed by a higher maintenance dose. However, these studies have not focused on individual changes. OBJECTIVES: This study examined the platelet function effects of increasing the maintenance clopidogrel dose from 75 to 150 mg/day with a focus on inter-individual response. PATIENTS/METHODS: Twenty patients with known coronary artery disease receiving 75 mg/day clopidogrel were recruited and given 150 mg/day clopidogrel for 30 days, then returned to 75 mg/day for an additional 30 days. Platelet function was assessed through light-transmittance aggregometry (LTA) and the VerifyNow P2Y12 assay at baseline, 30 days, and 60 days. RESULTS: Mean platelet inhibition was significantly improved with the increased maintenance dose when measured by the VerifyNow P2Y12 assay (P2Y12 reaction units: 191±15 vs. 158±17, P=0.013), but not when measured by LTA (LTA-adenosine diphosphate 5: 40±3 vs. 36±3, P = 0.11; LTA-adenosine diphosphate 20: 50±3 vs. 47±3, P = 0.23). However, only 50% of individual patients experienced improved platelet inhibition, as measured by the VerifyNow P2Y12 assay, when treated with the increased maintenance dose. Furthermore, poor baseline platelet response did not predict improved responsiveness at the increased dose. CONCLUSION: Despite changing the population's mean antiplatelet response, an increased maintenance dose of clopidogrel did not improve antiplatelet response in a substantial number of patients; nor did baseline platelet function predict response to a higher maintenance dose.

UR - http://www.scopus.com/inward/record.url?scp=66349118978&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=66349118978&partnerID=8YFLogxK

U2 - 10.1097/MCA.0b013e328329924b

DO - 10.1097/MCA.0b013e328329924b

M3 - Review article

VL - 20

SP - 207

EP - 213

JO - Coronary Artery Disease

JF - Coronary Artery Disease

SN - 0954-6928

IS - 3

ER -